Kirkland Advises J.P. Morgan Private Capital on Close of Inaugural Biotechnology Venture Fund over $500 million

Kirkland advised J.P. Morgan Private Capital on the final closing of its inaugural biotechnology venture capital fund, 270 Life Sciences Private Capital Fund I. The fund closed above its $500 million target, attracting strong support from investors, including institutional allocators, strategic corporate partners, family offices and high net worth individuals across North America, Europe, the Middle East and Asia. The fund invests in private biotechnology companies across stage, modality, therapeutic area, and geography. The fund’s early company formation activities and portfolio investments span cardiometabolic disease, oncology, immunology and genetic medicines. The fund aims to leverage the scale and resources of J.P. Morgan to add value to its portfolio companies.

Read J.P. Morgan Private Capital’s Press Release

The team was led by investment funds partners Erica Berthou and Samara Shepherd.